Results 61 to 70 of about 1,131,860 (291)

Proteomic Analysis of Covalent Modifications of Tubulins by Isothiocyanates [PDF]

open access: yesThe Journal of Nutrition, 2012
Although isothiocyanates (ITC), which are found in cruciferous vegetables, have been shown to inhibit carcinogenesis in animal models and induce apoptosis and cell cycle arrest in tumor cells, the biochemical mechanisms of cell growth inhibition by these compounds are not fully understood.
Zhen, Xiao   +3 more
openaire   +2 more sources

Synergistic effects of plasma polymerization and covalent surface modification of carbon fibers

open access: yes, 2021
Synergistic effects of plasma polymerization and covalent surface modification of carbon ...
DJ Eyckens (14451150)   +4 more
core  

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

open access: yesMolecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka   +9 more
wiley   +1 more source

Covalent Modification Cycles through the Spatial Prism [PDF]

open access: yesBiophysical Journal, 2013
Covalent modification cycles are basic units and building blocks of posttranslational modification and cellular signal transduction. We systematically explore different spatial aspects of signal transduction in covalent modification cycles by starting with a basic temporal cycle as a reference and focusing on steady-state signal transduction.
Alam-Nazki, Aiman, Krishnan, J.
openaire   +2 more sources

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

open access: yesMolecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington   +10 more
wiley   +1 more source

Covalent modifications of histones during mitosis and meiosis [PDF]

open access: yesCell Cycle, 2009
Higher order chromosome structures are the hallmark of mitotic and meiotic cells. Chromatin condensation and compaction are essential for rapid chromosome congression and accurate chromosome segregation during cell division. The core histones possess tails at their amino-termini. These tails, which extend from the surface of the nucleosomes, are highly
Dazhong, Xu   +4 more
openaire   +2 more sources

Selection of antibody-binding covalent aptamers

open access: yesCommunications Chemistry
Aptamers are oligonucleotides with antibody-like binding function, selected from large combinatorial libraries. In this study, we modified a DNA aptamer library with N-hydroxysuccinimide esters, enabling covalent conjugation with cognate proteins.
Noah Soxpollard   +3 more
doaj   +1 more source

Synergistic effects of plasma polymerization and covalent surface modification of carbon fibers

open access: yes, 2023
Synergistic effects of plasma polymerization and covalent surface modification of carbon ...
Luke Henderson (13082367)   +4 more
core  

Modelling covalent modification of cysteine residues in proteins

open access: yes, 2020
Cysteine is a unique amino acid because of the chemical reactivity of its thiol (–SH) side chain. For that reason, cysteine serves several essential roles in biochemistry, and its reactivity is critical for the catalytic activity of several biological ...
Awoonor-Williams, Ernest
core   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

open access: yesMolecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy